Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
Question
Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
Direct answer
Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications. — bullish pressure on JNJ.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-28
- Revision
- 1 · 2026-10-29
Cite as: Market Ontology, “Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/johnson-johnson-amivantamab-combo-reports-77-response-rate-in-head-and-neck-canc-66af89
Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications. — bullish pressure on JNJ.
Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.
- SummaryJohnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.
- JNJDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- JNJ closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JNJ price vs. pre-event level
- JNJ volume vs. 20-day average
Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications. — bullish pressure on MRK.
Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.
- SummaryJohnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.
- MRKDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- MRK closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- MRK price vs. pre-event level
- MRK volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Bullish | 266.30 2026-10-26 | Pending | Pending | Pending |
| MRK | Bullishagreed | 140.61 2026-10-26 | +0.86% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.